Hesselbjerg, Louise Justesen <br/><br/>
Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide.  [electronic resource] 

 -  Journal of medical economics  Jul 2013 
 - 845-58 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.3111/13696998.2013.800523  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticoagulants--adverse effects<br/>Atrial Fibrillation--drug therapy<br/>Benzimidazoles--administration & dosage<br/>Cost-Benefit Analysis<br/>Dabigatran<br/>Embolism--prevention & control<br/>Hemorrhage--chemically induced<br/>Humans<br/>Quality-Adjusted Life Years<br/>Stroke--prevention & control<br/>Warfarin--administration & dosage<br/>beta-Alanine--administration & dosage